Skip to main content
. Author manuscript; available in PMC: 2011 Jun 30.
Published in final edited form as: Respir Physiol Neurobiol. 2010 Apr 23;172(1-2):42–52. doi: 10.1016/j.resp.2010.04.008

Table 1.

5-HT3 agonists 5-HT3 antagonists
mCPBG PBG Tropisetron MDL72222
Burst Duration (s)
Baseline 12.0 ± 0.8 11.8 ± 0.8 11.8 ± 1.0 11.0 ± 1.2
Drug Application 9.7 ± 0.8 12.2 ± 0.6 9.0 ± 1.4 7.3 ± 1.0*
Washout 9.2 ± 0.9* 11.5 ± 0.7
Percent Time-to-Peak
Baseline 28 ± 6 40 ± 2 24 ± 4 19 ± 4
Drug Application 31 ± 7 43 ± 2 17 ± 3 13 ± 3
Washout 25 ± 5 41 ± 2
Amplitude (normalized)
Baseline 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00
Drug Application 0.94 ± 0.05 0.98 ± 0.02 0.72 ± 0.05* 0.80 ± 0.04*
Washout 0.89 ± 0.05 0.94 ± 0.02

Percent time-to-peak is the time-to-peak (s) divided by peak duration (s). Amplitude is normalized to baseline values.

The asterisk indicates p<0.05 compared to baseline.